Skip to content
OpenCapital
Get started

Boston Scientific BSX Free cash flow

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
TFX
TeleflexTFX
$27.87M+676%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
Haemonetics logo
HaemoneticsHAE
$53.28M-47.2%
CONMED logo
CONMEDCNMD
$10.58M-72.0%

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%

Valuation

See full
Market cap$65.7B-56.2%
P/E18.5×-55.6×
P/S3.2×-5.4×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Calculated from Boston Scientific’s reported figures.

$348.0Mnet cash from operating−$177.0Mcapital expenditures=$171M

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's free cash flow?
Boston Scientific (BSX) reported free cash flow of $171M in Q1 2026.
How has Boston Scientific's free cash flow changed year-over-year?
Boston Scientific's free cash flow decreased by 51.7% year-over-year, from $354M to $171M.
What is the long-term trend for Boston Scientific's free cash flow?
Over 4 years (2021 to 2025), Boston Scientific's free cash flow has grown at a 29.1% compound annual growth rate (CAGR), from $1.32B to $3.66B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.